Patients had longer median progression-free survival rates with anlotinib vs with placebo in a phase 2 trial, but overall survival data were still immature.
Sabrina Serani
Sabrina Serani is the assistant managing editor for Targeted Oncology.
Articles by Sabrina Serani
Researchers used split-dose busulfan, fludarabine, and post-transplant cyclophosphamide on 6 patients in a phase 2 study, and further research is warranted.
Tislelizumab met its primary end point of overall survival and exceeded that of sorafenib in patients with unresectable hepatocellular carcinoma.
In a phase 2 trial, BXCL701 and pembrolizumab showed a significant increase in median overall survival time for patients with small cell neuroendocrine prostate cancer.
Bexmarilimab shows encouraging results when combined with standard of care treatments for patients with acute myeloid leukemia and myelodysplastic syndromes.
The CXCL 12 inhibitor delivered a 50% overall survival rate at 18 months in the GLORIA trial, and its manufacturer intends to seek FDA guidance on further trial design.
The next-generation diagnostic tool is approved for companion diagnostic use with selpercatinib for select solid locally advanced and metastatic tumors.
Researchers identified different functions of groups of intraepithelial T cells (T-IELs) throughout the gastrointestinal tract, which could help inform future immunological treatment for patients with colorectal cancer.
The CAR-HEMATOTOX score was positively associated with identifying the risk of poor treatment outcomes for patients with mantle cell lymphoma treated with chimeric antigen receptor T-cell therapy.
The FDA completed its inspection of a third-party filler, and no additional data or trials have been requested for resubmission.
Investigators presented results from new studies at the 2023 ASTRO Meeting. The data showcase a new assay’s performance in predicting metastasis-free survival and distant metastasis.
The improvement in progression-free survival in the venetoclax arm of the study was not statistically significant compared to the control arm but results still trend positively.
Meeting a primary end point, KEYNOTE-123 study shows promise for pembrolizumab as an adjuvant muscle-invasive bladder cancer treatment.
The decision marks the first time the FDA has relied on a single externally controlled trial to support a potential approval in oncology.
The phase 1/2 trial is evaluating 64Cu/67Cu SAR-Bombesin for diagnosis and treatment of castrate resistant prostate cancer.
Phase 2 studies are investigating BDC-1001 in HER2-positive gastroesophageal, colorectal, breast, and endometrial cancers.
An MCGN drug combination shows potential to be more effective than standard chemotherapy alone for treatment-naïve metastatic pancreatic cancer.
Results of the phase 3 MIRASOL study evaluating mirvetuximab soravtansine for platinum-resistant ovarian cancer will be announced at an upcoming meeting.
Researchers presented updated results from longer-term follow-up studies of GC012F for newly-diagnosed multiple myeloma treatment at the International Myeloma Society Annual Meeting.